Acceptance of an ABO-Incompatible Mismatched (AB+ to O+) Liver Allograft With the Use of Daclizumab and Mycophenolate Mofetil

Liver Transplantation

Volumn 6, Issue 4, 2000, Pages 497-500

  Fang, W Christopher ^a   Saltzman, John ^a   Rososhansky, Sarah ^a   Szabo, Gyongi ^a   Heard, Stephen O ^a   Banner, Barbara ^a   Chari, Ravi ^a   Katz, Eliezer ^a  

^a UNIVERSITY OF MASSACHUSETTS   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; DALFOPRISTIN PLUS QUINUPRISTIN; INTERLEUKIN 2 RECEPTOR ANTIBODY; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; OKT 3; PROSTAGLANDIN E1; STEROID; TACROLIMUS;

ADULT; ALLOGRAFT; ARTICLE; BLOOD GROUP ABO SYSTEM; CASE REPORT; FEMALE; GRAFT REJECTION; HUMAN; HUMAN TISSUE; IMMUNOSUPPRESSIVE TREATMENT; LIVER BIOPSY; LIVER TRANSPLANTATION; PLASMAPHERESIS; PRIORITY JOURNAL;

EID: 0033929528     PISSN: 15276465     EISSN: None     Source Type: Journal    
DOI: 10.1053/jlts.2000.6448     Document Type: Article

References (8)

1. Liver transplantation across ABO blood group
2. The use of ABO-incompatible grafts in liver transplantation: A life-saving procedure in highly selected patients
3. ABO blood-group incompatibility in liver transplantation: A single-centre experience
4. Successful use of an enhanced immunosuppressive protocol with plasmapheresis for ABO-incompatible mismatched grafts in liver transplant recipients
5. Risk factors for liver transplantation across the ABO barrier
6. 2 renal antibodies
7. Resistant hepatic allograft rejection successfully treated with cyclophosphamide and plasmapheresis
8. Interleukin-2-receptor blockade with daclizumab to prevent acute rejection in renal transplantation. Daclizumab Triple Therapy Study Group